Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24366859 | 0.86 | ALDH1A1 (0.47) | PRMT5KDM4EALDH1A1MKNK1MKNK2 | |
| SCHEMBL6085720 | 0.86 | SIRT2 (0.53) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| SCHEMBL24363837 | 0.85 | SIRT2 (0.49) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| SCHEMBL24365372 | 0.84 | SIRT2 (0.46) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| Hydrochloric Acid SCHEMBL29477655 | 0.83 | SIRT2 (0.48) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| Hydrochloric Acid SCHEMBL29081257 | 0.83 | SIRT2 (0.48) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| Lithium Ion SCHEMBL29081628 | 0.82 | SIRT2 (0.47) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| Lithium Ion SCHEMBL29477410 | 0.82 | SIRT2 (0.47) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| SCHEMBL28284703 | 0.81 | SIRT2 (0.51) | SIRT2SIRT3SIRT1PRMT5KDM4E | |
| SCHEMBL24755950 | 0.80 | ALDH1A1 (0.49) | SIRT2SIRT3SIRT1PRMT5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SIRT2 1365/4885SIRT3 559/4885SIRT1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.